0001415889-24-009989.txt : 20240403
0001415889-24-009989.hdr.sgml : 20240403
20240403161513
ACCESSION NUMBER: 0001415889-24-009989
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: St Leger Tina Amber
CENTRAL INDEX KEY: 0001969525
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39992
FILM NUMBER: 24818879
MAIL ADDRESS:
STREET 1: C/O IMMUNOCORE LIMITED
STREET 2: 92 PARK DRIVE, MILTON PARK, ABINGDON
CITY: OXFORDSHIRE
STATE: X0
ZIP: OX14 4RY
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunocore Holdings plc
CENTRAL INDEX KEY: 0001671927
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 90 PARK DRIVE
STREET 2: MILTON PARK, ABINGDON
CITY: OXFORDSHIRE
STATE: X0
ZIP: OX14 4RY
BUSINESS PHONE: 01235 5430281
MAIL ADDRESS:
STREET 1: 90 PARK DRIVE
STREET 2: MILTON PARK, ABINGDON
CITY: OXFORDSHIRE
STATE: X0
ZIP: OX14 4RY
FORMER COMPANY:
FORMER CONFORMED NAME: Immunocore Ltd
DATE OF NAME CHANGE: 20160412
4
1
form4-04032024_040401.xml
X0508
4
2024-04-01
0001671927
Immunocore Holdings plc
IMCR
0001969525
St Leger Tina Amber
C/O IMMUNOCORE HOLDINGS PLC
92 PARK DRIVE, MILTON PARK, ABINGDON
OXFORDSHIRE
X0
OX14 4RY
UNITED KINGDOM
false
true
false
false
CHIEF HR OFFICER
1
Ordinary Shares
2024-04-01
4
M
0
4375
29.87
A
4375
D
Ordinary Shares
2024-04-01
4
S
0
4375
64.06
D
0
D
Employee Share Option (Right to Buy)
29.87
2024-04-01
4
M
0
4375
0
D
2032-03-31
Ordinary Shares
4375
35000
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.73 to $64.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option award vested on April 1, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
/s/ Lily Hepworth, Attorney-in-Fact
2024-04-03